Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate

Esson, Raphaël; Sousa, Emanuel Rodrigues de; Benair, Loïc; Devard, Nicolas; Soulet, D.; Gillet, Audrey; Bassard, Isabelle; Falque, Stephanie; Chareyre, Audrey; Marmin, Morgane; Girerd-Chambaz, Yves; Logvinoff, Carine; Sanchez, M.E. Navarro

doi:10.1016/j.vaccine.2022.07.043

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Actualmente, el refuerzo de dosis de la vacuna 17D (anti-amarilla) ha sido muy cuestionado por el tiempo de la memoria inmunológica que induce y la evidencia que sugiere que la protección es por diez años, sin embargo esta dosis de refuerzo puede ser beneficiosa para epidemias y endemias, especialmente en aquellas inmunizados en la infancia (Araujo et al, 2022;Esson et al, 2022). Estos datos son alarmantes debido a la escasa cobertura poblacional de vacunación anti amarilla, por lo que debe ser un punto de partida para investigar la efectividad de la vacuna contra la fiebre amarilla en nuestra población.…”

Section: Discussionunclassified

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Montalvo

Díaz-Lazo²,

Montalvo³

et al. 2022

BMSA

View full text Add to dashboard Cite

En los centros de Emergencia con poco apoyo de laboratorio, es difícil diferenciar a los pacientes con dengue grave y fiebre amarilla severa. El objetivo fue comparar el perfil clínico y de laboratorio de los pacientes con dengue grave y fiebre amarilla severa en Urgencias. Se realizó un estudio observacional retrospectivo de pacientes con diagnóstico confirmado de dengue y fiebre amarilla en el período 2018 a 2020 atendidos en la Unidad de Emergencia del Hospital Carrión, Huancayo-Perú. Se evaluaron un total de 35 pacientes, 11 pacientes (31,4%) fueron diagnosticados con fiebre amarilla severa y 24 pacientes (68,5%) con dengue grave. La media de los resultados de laboratorio con fiebre amarilla severa fueron bilirrubina indirecta 4,7 ml/dL, aspartato transaminasa 4463 UI/L, transaminasa aminotransferasa 4329 UI/L, creatinina 4,9 mg/dl. En pacientes con dengue grave el hematocrito promedio fue 51,8, hemoglobina 17,6 g/dl, plaquetas 24 × 103/mm. En pacientes con síndrome ictérico-febril la presencia de bradicardia, bilirrubina indirecta elevada y transaminasas muy elevadas debe hacer sospechar de fiebre amarilla; mientras que los pacientes que acuden por ascitis, derrame pleural, aumento de hematocrito y deficiencia de plaquetas, se debe tratar como dengue grave sobre todo en Unidades de Emergencia con poco apoyo de laboratorio.

show abstract

Section: Discussionunclassified

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Montalvo

Díaz-Lazo²,

Montalvo³

et al. 2022

BMSA

View full text Add to dashboard Cite

show abstract

“…This low diversity may limit viral dissemination in mosquitoes [ 24 ]. As vYF-247 derives from YFV-17D, it is probable that both vaccines share some properties [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes

et al. 2022

View full text Add to dashboard Cite

One of the most effective vaccines against an arbovirus is the YFV-17D live-attenuated vaccine developed in 1937 against Yellow Fever (YF). This vaccine replicates poorly in mosquitoes and consequently, is not transmitted by vectors. Vaccine shortages, mainly due to constrained productions based on pathogen-free embryonated eggs, led Sanofi to move towards alternative methods based on a state-of-the-art process using continuous cell line cultures in bioreactor. vYF-247 is a next-generation live-attenuated vaccine candidate based on 17D adapted to grow in serum-free Vero cells. For the development of a new vaccine, WHO recommends to document infectivity and replication in mosquitoes. Here we infected Aedes aegypti and Aedes albopictus mosquitoes with vYF-247 vaccine compared first to the YF-17D-204 reference Sanofi vaccines (Stamaril and YF-VAX) and a clinical human isolate S-79, provided in a blood meal at a titer of 6.5 Log ffu/mL and secondly, to the clinical isolate only at an increased titer of 7.5 Log ffu/mL. At different days post-infection, virus replication, dissemination and transmission were evaluated by quantifying viral particles in mosquito abdomen, head and thorax or saliva, respectively. Although comparison of vYF-247 to reference vaccines could not be completed to yield significant results, we showed that vYF-247 was not transmitted by both Aedes species, either laboratory strains or field-collected populations, compared to clinical strain S-79 at the highest inoculation dose. Combined with the undetectable to low level viremia detected in vaccinees, transmission of the vYF-247 vaccine by mosquitoes is highly unlikely.

show abstract

“…Recent insights and open questions regarding efficacy and safety [9], epidemiology [10,11] and future developments in the field of yellow fever vaccination [12] are discussed elsewhere. Approaches on how to overcome issues of disruptions and shortages of YF17D supply by fractional dosing [3,13], dosing via the intradermal route [14], or modern state-ofthe-art bioprocess engineering [15], moving away from classical egg-based production [16][17][18], are out of the scope of this review.…”

mentioning

confidence: 99%

YF17D‐based vaccines – standing on the shoulders of a giant

Sanchez‐Felipe,

Alpizar,

et al. 2024

Eur J Immunol

View full text Add to dashboard Cite

SummaryLive‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.

show abstract

Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate

Cited by 5 publications

References 23 publications

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Comparación clínica y laboratorial de la fiebre amarilla severa versus dengue grave en Perú

Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes

YF17D‐based vaccines – standing on the shoulders of a giant

Contact Info

Product

Resources

About